In this webinar, the featured speakers will talk about the contribution and convenience of in vitro human cell assays using primary-like human beta cells and associated tools for diabetes research. Optimized physiological, functional, and pharmacologically predictive in vitro models have the potential to accelerate drug discovery and development, prompting safer and more efficient drugs.
EndoC-βH5 cells are a recently established human beta-cell model. These cells represent a unique storable and ready-to-use tool with highly robust and reproducible features. This model, when exposed to different stimuli is thus relevant for the study of beta-cell function, screening and validation of new drugs, and development of disease models.
As an example, glucose stimulation of the EndoC-βH5 cells will result in the secretion of insulin in a dynamic manner and this secretion can be enhanced by GLP-1 (glucagon‐like peptide) and GIP (glucose‐dependent insulinotropic polypeptide) analogs. In this way, EndoC-βH5 based disease models for T1 and T2 diabetes, allow lead identification and optimization in drug development without compromising highly reproducible results and providing an accurate understanding of beta-cell function. Thus, showing that EndoC-βH5 cells can grant relevant early drug discovery through beta-cell function characterization and target identification and validation approaches.
Join the featured speakers as they discuss existing models and solutions for biomedical research and drug development in diabetes based on the newly developed EndoC-βH5 primary-like human beta cells, which combine robust glucose-stimulated insulin secretion and GLP-1/GIP receptor activities and modeling of human T1 & T2 diabetes.
Bruno Blanchi, PhD, Chief Scientific Officer, Human Cell Design
Bruno Blanchi is currently responsible for the R&D strategy and development of new products, models and solutions at Human Cell Design. Bruno holds a PhD in Immunology and has an extensive experience in cellular systems and control of cell differentiation and specification with over 20 years of experience in hiPSC-derived models, human cellular models and disease modeling. Bruno also has extensive expertise in model and assay development including various tools and techniques that include gene targeting, gene expression measurement, microscopy and functional assays. Overall, Bruno, together with the Human Cell Design team, are experts in developing physiological and pharmacologically predictive functional human cellular models, assays and services.
Miguel Sáinz Jaspeado, PhD, Scientific Affairs Manager, Mercodia
Miguel Sainz has a PhD in biomedical research and vast experience in tumor and vascular biology. With over 15 years of scientific experience in translational and basic research, Miguel is responsible for the development of scientific strategies for Mercodia, in alignment with the company’s global view building and maintaining scientific and medical partnerships. He has worked with multiple experimental models (in vitro and in vivo) and evaluation methods for protein analysis and signalling including microscopy, cytometry, immunochemistry, protein analysis and protein interaction.
Who Should Attend?
This webinar will appeal to professionals in the following fields:
- Researchers in the field of diabetes
- Pharma companies in the field of diabetes
What You Will Learn
Attendees will gain insights into:
- The most recent assays and disease models for T1 and T2 diabetes that have been developed using the fully functional and standardized EndoC-βH5 human beta cells
Mercodia is a world-leading manufacturer of cardiometabolic immunoassays using our 30+ years of experience to provide tailored bioanalysis solutions for pharma and biotech companies. We specialize in assay development and validation, PK/PD, immunogenicity testing, and biomarker analysis, mainly focusing on large molecules, peptides, and oligonucleotide therapeutics in preclinical and clinical development. We are GLP-certified and work in accordance with ICH GCP, EMA, and FDA guidelines.
Mercodia’s vision is to improve human health by offering our products and services to scientists around the globe. Our team of experts quickly provides reproducible, reliable, and high-quality data that meets regulatory requirements. We prioritize speed and flexibility while delivering cost-effective solutions and are a trusted partner to some of the most renowned universities, pharmaceutical, and biotech companies worldwide.